Healthy Non-Obese Adults (2010-2012)
- Develop better predictive equations for BMR in healthy Chinese adults
 - Evaluate factors that may influence BMR.
 
Definitions
- Steady state: VO2and CO2measurements obtained every 30-secs until equilibrium achieved for at least 5 to 6 consecutive minutes
 - Harris-Benedict equation: Cited 1918 study
 - Ideal body weight: Cited Huang 1992 for Chinese persons
 - Body fat: Siri’s equation, 1961
 - Body Surface Area (BSA) equation: used formula derived from Dubois and Dubois
 - Body Cell Mass (BCM) equation: Used Moore equation
 - Fat-free mass (FFM): Body weight (1-%body fat).
 
- Understand and give written consent
 - Healthy
 - Normal weight for Chinese persons (based on equations derived by Huang et al for Chinese persons).
 
- Refusal to consent
 - Hx of current illnesses
 - Recent weight loss
 - Endocrine disorders
 - Pharmacologic therapy
 - Hormonal treatment
 - Extremely underweight (<80% IBW) or obese (120% IBW).
 
Recruitment
Procedures not described
Design
Cross-sectional study
Subjects stratified on basis of gender and age (20-29, 30-39, 40-49, 50-59, 60+ years)
Blinding used
Not applicable
Intervention
Not applicable
Statistical Analysis
- Student's T-test used to assess differences between men and women
 - Pearson correlation coefficients and linear regression analyses used to evaluate relationships between measured BMR and age, weight, height, percentage ideal body weight, percent body fat, fat-free mass, body surface area and body cell mass results expressed as mean±standard deviation (SD)
 - Cross-validation study: Sample was randomly divided into two groups for development and cross-validation of predictive equations; there were no differences in body composition parameters between each sample.
 
 
Timing of measurements
One measurement time
Dependent variables
- Measured BMR: Indirect calorimetry [(VO2, liters per minute), VCO2 (liters per minute; ml/kg per minute)].
    
- C type: Metabolic cart with a canopy system
 - Rest before measure: “Relaxed supine position”
 - Fasting length: 12 hours; Measured between 8-10 a.m.
 - Exercise conditioning 24 prior to test: Refrain 12 hours before test
 - Smoking: Refrain one hour before test
 - Room temp: Not reported
 - No. of measures were they repeated? O2 and CO2 taken at 30 second intervals until a steady-state was achieved and maintained for at least five to six consecutive minutes
 - Steady state: VO2 and CO2 measurements obtained every 30-seconds until equilibrium achieved for at least five to six consecutive minutes
 - Coefficient of variation? None reported
 - Equipment of Calibration: None reported
 - Training of measurer? Dietitians trained to use a standardized protocol
 - Subject training of measuring process? None reported
 - Sleep at the facility: Not reported
 - Monitored heart rate? None reported
 - Body temperature? None reported.
 
 
Independent variables
- Predicted REE using HB, Mifflin, Owen (men), Owen(women), Kleiber, Cunningham
    
- Harris-Benedict equation: Cited 1918 study
 
 - Height: Method not reported
 - Weight: Method not reported
 - Body mass index (BMI: kg/m2
 - Ideal body weight: based on Huang, 1992 for Chinese persons
 - Body composition (body fat and fat free mass): sum of skinfolds (biceps, triceps, subscapular, suprailiac) and bioelectrical impednace analysis, resistance and reactance
    
- Body fat: Siri’s equation, 1961
 - Fat free mass (FFM): body weight (1% body fat)
 
 - Body Surface Area (BSA) equation: Formula derived from Dubois and Dubois
 - Body Cell Mass (BCM) equation: Moore equations for males and females.
 
Control variables
Age and gender: Sample stratified
- Initial N: Not given
 - Attrition (final N): N=223 Chinese adults (N=102 males; N=121 females)
 - Age: Mean age: 43.8±14.3 years; range: 20-78 years
 - Ethnicity: Chinese
 - Anthropometrics:
 
| Men N=102 Mean±SD | Women N=121 Mean ±SD | |
| Weight, kg | 63.5±7.6 | 52.9±5.0* | 
| Height, cm | 167.5±5.3 | 157±4.0* | 
| BMI | 22.6±2.4 | 21.5±2.2 | 
| BFS, percent | 15.2±4.4 | 28.6±4.2* | 
| BFB, percent | 15.7±3.7 | 27.6±3.7*# | 
| FFMS, kg | 53.7±5.2 | 37.6±2.7* | 
| FFMB, kg | 53.4±6.1 | 38.2±2.8* | 
| BCM, kg | 25.8±3.2 | 17.9±1.3* | 
| BSA, m2 | 1.72±0.11 | 1.51±0.08* | 
| %IBW | 103.7±10.9 | 101.3±9.8 | 
- BFS: Body fat measured by BIA; BFB- Body fat measured by bioelectrical impedance analysis; FFMS-fat-free mass measured by skinfold thicknesses; FFMB- fat-free mass measured by BIA, BCM-body cell mass; BSA- body surface area
 - * Significantly different from men at P=0.0001
 - # Significantly different from BFS at P=0.02.
 - Location: Taipei, Taiwan.
 
Pearson Correlation Coefficients between:
- BMR and weight: 0.77
 - BMR and height: 0.73
 - BMR and age: -0.25
 - BMR and percent IBW: 0.33
 - BMR and BFS: -027
 - BMR and BFB: -0.34
 - BMR and FFMS: 0.84
 - BMR and FFMB: 0.86
 - BMR and BSA: 0.80
 - BMR and BCM: 0.89.
 
BMR best correlated with body cell mass (BCM) and BCM correlated best with fat-free mass by BIA (R=0.94). There was a negative correlation between BCM and age (-0.28).
BMR adjusted for body composition and body surface area
| Male N=102 | Female N=121* | |
| 
             BMR/weight kcal/kg  | 
            22±2 | 20±2* | 
| 
             BMR/FFM kcal/kg  | 
            26±2 | 28±3* | 
| 
             BMR/BCM kcal/kg  | 
            54±4 | 59±5* | 
| BMR/BSA kcal/m2 | 799±69 | 700±76 | 
* P=0.0001
Clinical: Resting energy expenditure
| Male Mean±SD | Female Mean±SD | |
| VO2 (mL/min) | 197±23 | 153±16* | 
| VCO2 (mL/min) | 175±21 | 134±16* | 
| RQ | 0.89±0.05 | 0.88±0.05 | 
- P=0.0001
 
Differences between measured and predicted RMR in males and females comparison measured BMR and estimate BMR (i.e., total sample) by different predictive equations
[Taken from Liu HY, Lu YF, Chen WJ. Validity of predictive equations for the calculation of basal metabolic rate in healthy Chinese adults. Chinese Nutr Soc. 1994; 19 (2): 141-150.]
| Kcal/day (±SD) | (Percent±SD) | |
| 
             Males, N=102; Females, N=121  | 
            ||
| Measured | 1,202±207 | |
| 
             Harris & Benedict  | 
            1,3?5±170 | (114±11%) | 
| 
             Mifflin  | 
            1,288±198 | (108±9%) | 
| 
             Owen  | 
            1,336±185 | (112±11%) | 
Differences between measured and predicted RMR in males and females
| Kcal per day (±SD) | (Percent±SD) | |
| 
             Males, N=102  | 
            ||
| 
             Measured  | 
            1,372±175 | |
| 
             Harris & Benedict  | 
            1,481±167 | (108±8%) | 
| 
             Mifflin  | 
            1,470±131 | (108±8%) | 
| Owen | 1,527±77 | (112±11%) | 
| 
             Females, N=121  | 
            ||
| 
             Measured  | 
            1,058±113 | |
| 
             Harris & Benedict  | 
            1,258±70 | (119±11%) | 
| 
             Mifflin  | 
            1,135±82 | (108±10%) | 
| Owen | 1,176±36 | (112±11%) | 
Developing predictive equations
The men and women in the two samples (validation and cross-validation) were comparable in age, anthropometric measurements (height and weight), body composition (including percent body fat, fat-free mass and body cell mass) and body surface area.
The mean difference, r and P-value for paired T-test results between predicted BMR (X-var) and measured BMR (Y-var) using cross-validation sample (N=104):
| Mean difference  (kcal per day)  | 
            r | P-value | |
| 
             HB  | 
            158±111 | 0.84 | 0.0001 | 
| Cunningham (Uses FFM variable)  | 
            278±111 | 0.85 | 0.0001 | 
| 
             Owen  | 
            137±114 | 0.84 | 0.0001 | 
| 
             Mifflin  | 
            92±97 | 0.88 | 0.0001 | 
| 
             Kleiber  | 
            262±142 | 0.73 | 0.0001 | 
| 
             Mifflin  | 
            117 | 0.44 | 0.0001 | 
- All of the available predictive equations overestimated BMR in healthy Chinese adults (P=0.0001)
 
The mean difference, r and P-value for paired T-test results between predicted BMR (X-var) and measured BMR (Y-var) in cross-validation sample (N=104)
| Mean difference  (kcal per day)  | 
            r | P-value | |
| 
             C3  | 
            7±96 | 0.89 | 0.4497 | 
| 
             C5  | 
            6±100 | 0.88 | 0.5630 | 
| 
             C6  | 
            5±98 | 0.88 | 0.6294 | 
| 
             C7  | 
            7±101 | 0.87 | 0.5078 | 
| C8 | 7±101 | 0.87 | 0.5078 | 
- No significant differences were observed between measured BMR and predicted values estimated by the nine equations developed in this study
 
[NOTE: The four equations above are discussed due to availability of obtaining the factors needed.]
- The BMR was estimated in 10 randomly selected subjects from the cross-validation study using Mifflin et al equation and equation 8
 - Significant differences were observed between BMR estimated by Mifflin and measured BMR (P=0.0001). No significant differences were observed between measured BMR and BMR estimated by equation 8.
 
As stated by the author in body of report:
- In our study, women had a lower metabolic rate than men because of a relatively smaller amount of body cell mass; the result of smaller skeletal muscle mass in tandem with greater fat mass.
 - The major difference between men and women was the difference in amount of skeletal muscle mass
 - Previous findings suggest resting energy expenditure correlated most highly with fat-free mass, which correlated highly with weight and height. Our results agree that accurate determination of height and weight, not calorimetry or assessment of body composition are needed to provide a base for estimating daily energy expenditure of individual mean and women.
 - Fat-free mass was the best single predictor of BMR and could explain 75% of the variance observed among people... the same r2 value was obtained when body weight and body height were used to substitute fat-free mass for predicting BMR. The use of four variables-body weight, body height, age and sex resulted in an r2 value of 0.81. 81% of the variance in BMR among persons was accounted for by the covariates of weight, height, age and sex.
 - A significant degree of overestimation was still observed in predicting BMR in Chinese adults using the Mifflin et al equations (P=0.0001)
 - We do not know if predictive equations overestimated BMR for Chinese adults is the result of ethnic differences or other factors such as climate and lifestyle
 - We recommend these [our] equations for clinical use in healthy Chinese adults who are within normal limits for body weight.
 
| Government: | Dept. of Health-Republic of China | 
Strengths
Selected an important ethnic group within a healthy population.
Generalizability/Weaknesses
- Large study population represented and stratified by age
 - Cross-validated equations on separate stratified sample
 - Study weaknesses include:
    
- No subject training prior to measurement; did not sleep over at facility where measurement being taken-hence definition of “BMR” is most likely “Resting metabolic rate”
 - Room temperature not reported
 - Sample represents Chinese adults living in Taipei, Taiwan, Republic of China; Hence, considering lifestyle differences-limited generalizability to US-residing Chinese population.
 
 
| 
	 Quality Criteria Checklist: Primary Research 
   | 
 |||
| Relevance Questions | |||
| 1. | Would implementing the studied intervention or procedure (if found successful) result in improved outcomes for the patients/clients/population group? (Not Applicable for some epidemiological studies) | Yes | |
| 1. | Would implementing the studied intervention or procedure (if found successful) result in improved outcomes for the patients/clients/population group? (Not Applicable for some epidemiological studies) | Yes | |
| 2. | Did the authors study an outcome (dependent variable) or topic that the patients/clients/population group would care about? | Yes | |
| 2. | Did the authors study an outcome (dependent variable) or topic that the patients/clients/population group would care about? | Yes | |
| 3. | Is the focus of the intervention or procedure (independent variable) or topic of study a common issue of concern to dieteticspractice? | Yes | |
| 3. | Is the focus of the intervention or procedure (independent variable) or topic of study a common issue of concern to dieteticspractice? | Yes | |
| 4. | Is the intervention or procedure feasible? (NA for some epidemiological studies) | Yes | |
| 4. | Is the intervention or procedure feasible? (NA for some epidemiological studies) | Yes | |
| Validity Questions | |||
| 1. | Was the research question clearly stated? | Yes | |
| 1. | Was the research question clearly stated? | Yes | |
| 1.1. | Was (were) the specific intervention(s) or procedure(s) [independent variable(s)] identified? | Yes | |
| 1.1. | Was (were) the specific intervention(s) or procedure(s) [independent variable(s)] identified? | Yes | |
| 1.2. | Was (were) the outcome(s) [dependent variable(s)] clearly indicated? | Yes | |
| 1.2. | Was (were) the outcome(s) [dependent variable(s)] clearly indicated? | Yes | |
| 1.3. | Were the target population and setting specified? | Yes | |
| 1.3. | Were the target population and setting specified? | Yes | |
| 2. | Was the selection of study subjects/patients free from bias? | ??? | |
| 2. | Was the selection of study subjects/patients free from bias? | ??? | |
| 2.1. | Were inclusion/exclusion criteria specified (e.g., risk, point in disease progression, diagnostic or prognosis criteria), and with sufficient detail and without omitting criteria critical to the study? | Yes | |
| 2.1. | Were inclusion/exclusion criteria specified (e.g., risk, point in disease progression, diagnostic or prognosis criteria), and with sufficient detail and without omitting criteria critical to the study? | Yes | |
| 2.2. | Were criteria applied equally to all study groups? | Yes | |
| 2.2. | Were criteria applied equally to all study groups? | Yes | |
| 2.3. | Were health, demographics, and other characteristics of subjects described? | Yes | |
| 2.3. | Were health, demographics, and other characteristics of subjects described? | Yes | |
| 2.4. | Were the subjects/patients a representative sample of the relevant population? | ??? | |
| 2.4. | Were the subjects/patients a representative sample of the relevant population? | ??? | |
| 3. | Were study groups comparable? | Yes | |
| 3. | Were study groups comparable? | Yes | |
| 3.1. | Was the method of assigning subjects/patients to groups described and unbiased? (Method of randomization identified if RCT) | N/A | |
| 3.1. | Was the method of assigning subjects/patients to groups described and unbiased? (Method of randomization identified if RCT) | N/A | |
| 3.2. | Were distribution of disease status, prognostic factors, and other factors (e.g., demographics) similar across study groups at baseline? | Yes | |
| 3.2. | Were distribution of disease status, prognostic factors, and other factors (e.g., demographics) similar across study groups at baseline? | Yes | |
| 3.3. | Were concurrent controls or comparisons used? (Concurrent preferred over historical control or comparison groups.) | Yes | |
| 3.3. | Were concurrent controls or comparisons used? (Concurrent preferred over historical control or comparison groups.) | Yes | |
| 3.4. | If cohort study or cross-sectional study, were groups comparable on important confounding factors and/or were preexisting differences accounted for by using appropriate adjustments in statistical analysis? | Yes | |
| 3.4. | If cohort study or cross-sectional study, were groups comparable on important confounding factors and/or were preexisting differences accounted for by using appropriate adjustments in statistical analysis? | Yes | |
| 3.5. | If case control study, were potential confounding factors comparable for cases and controls? (If case series or trial with subjects serving as own control, this criterion is not applicable.) | Yes | |
| 3.5. | If case control study, were potential confounding factors comparable for cases and controls? (If case series or trial with subjects serving as own control, this criterion is not applicable.) | Yes | |
| 3.6. | If diagnostic test, was there an independent blind comparison with an appropriate reference standard (e.g., "gold standard")? | N/A | |
| 3.6. | If diagnostic test, was there an independent blind comparison with an appropriate reference standard (e.g., "gold standard")? | N/A | |
| 4. | Was method of handling withdrawals described? | ??? | |
| 4. | Was method of handling withdrawals described? | ??? | |
| 4.1. | Were follow-up methods described and the same for all groups? | N/A | |
| 4.1. | Were follow-up methods described and the same for all groups? | N/A | |
| 4.2. | Was the number, characteristics of withdrawals (i.e., dropouts, lost to follow up, attrition rate) and/or response rate (cross-sectional studies) described for each group? (Follow up goal for a strong study is 80%.) | ??? | |
| 4.2. | Was the number, characteristics of withdrawals (i.e., dropouts, lost to follow up, attrition rate) and/or response rate (cross-sectional studies) described for each group? (Follow up goal for a strong study is 80%.) | ??? | |
| 4.3. | Were all enrolled subjects/patients (in the original sample) accounted for? | ??? | |
| 4.3. | Were all enrolled subjects/patients (in the original sample) accounted for? | ??? | |
| 4.4. | Were reasons for withdrawals similar across groups? | N/A | |
| 4.4. | Were reasons for withdrawals similar across groups? | N/A | |
| 4.5. | If diagnostic test, was decision to perform reference test not dependent on results of test under study? | N/A | |
| 4.5. | If diagnostic test, was decision to perform reference test not dependent on results of test under study? | N/A | |
| 5. | Was blinding used to prevent introduction of bias? | N/A | |
| 5. | Was blinding used to prevent introduction of bias? | N/A | |
| 5.1. | In intervention study, were subjects, clinicians/practitioners, and investigators blinded to treatment group, as appropriate? | N/A | |
| 5.1. | In intervention study, were subjects, clinicians/practitioners, and investigators blinded to treatment group, as appropriate? | N/A | |
| 5.2. | Were data collectors blinded for outcomes assessment? (If outcome is measured using an objective test, such as a lab value, this criterion is assumed to be met.) | N/A | |
| 5.2. | Were data collectors blinded for outcomes assessment? (If outcome is measured using an objective test, such as a lab value, this criterion is assumed to be met.) | N/A | |
| 5.3. | In cohort study or cross-sectional study, were measurements of outcomes and risk factors blinded? | N/A | |
| 5.3. | In cohort study or cross-sectional study, were measurements of outcomes and risk factors blinded? | N/A | |
| 5.4. | In case control study, was case definition explicit and case ascertainment not influenced by exposure status? | N/A | |
| 5.4. | In case control study, was case definition explicit and case ascertainment not influenced by exposure status? | N/A | |
| 5.5. | In diagnostic study, were test results blinded to patient history and other test results? | N/A | |
| 5.5. | In diagnostic study, were test results blinded to patient history and other test results? | N/A | |
| 6. | Were intervention/therapeutic regimens/exposure factor or procedure and any comparison(s) described in detail? Were interveningfactors described? | Yes | |
| 6. | Were intervention/therapeutic regimens/exposure factor or procedure and any comparison(s) described in detail? Were interveningfactors described? | Yes | |
| 6.1. | In RCT or other intervention trial, were protocols described for all regimens studied? | N/A | |
| 6.1. | In RCT or other intervention trial, were protocols described for all regimens studied? | N/A | |
| 6.2. | In observational study, were interventions, study settings, and clinicians/provider described? | Yes | |
| 6.2. | In observational study, were interventions, study settings, and clinicians/provider described? | Yes | |
| 6.3. | Was the intensity and duration of the intervention or exposure factor sufficient to produce a meaningful effect? | Yes | |
| 6.3. | Was the intensity and duration of the intervention or exposure factor sufficient to produce a meaningful effect? | Yes | |
| 6.4. | Was the amount of exposure and, if relevant, subject/patient compliance measured? | Yes | |
| 6.4. | Was the amount of exposure and, if relevant, subject/patient compliance measured? | Yes | |
| 6.5. | Were co-interventions (e.g., ancillary treatments, other therapies) described? | N/A | |
| 6.5. | Were co-interventions (e.g., ancillary treatments, other therapies) described? | N/A | |
| 6.6. | Were extra or unplanned treatments described? | N/A | |
| 6.6. | Were extra or unplanned treatments described? | N/A | |
| 6.7. | Was the information for 6.4, 6.5, and 6.6 assessed the same way for all groups? | N/A | |
| 6.7. | Was the information for 6.4, 6.5, and 6.6 assessed the same way for all groups? | N/A | |
| 6.8. | In diagnostic study, were details of test administration and replication sufficient? | N/A | |
| 6.8. | In diagnostic study, were details of test administration and replication sufficient? | N/A | |
| 7. | Were outcomes clearly defined and the measurements valid and reliable? | No | |
| 7. | Were outcomes clearly defined and the measurements valid and reliable? | No | |
| 7.1. | Were primary and secondary endpoints described and relevant to the question? | Yes | |
| 7.1. | Were primary and secondary endpoints described and relevant to the question? | Yes | |
| 7.2. | Were nutrition measures appropriate to question and outcomes of concern? | N/A | |
| 7.2. | Were nutrition measures appropriate to question and outcomes of concern? | N/A | |
| 7.3. | Was the period of follow-up long enough for important outcome(s) to occur? | Yes | |
| 7.3. | Was the period of follow-up long enough for important outcome(s) to occur? | Yes | |
| 7.4. | Were the observations and measurements based on standard, valid, and reliable data collection instruments/tests/procedures? | No | |
| 7.4. | Were the observations and measurements based on standard, valid, and reliable data collection instruments/tests/procedures? | No | |
| 7.5. | Was the measurement of effect at an appropriate level of precision? | Yes | |
| 7.5. | Was the measurement of effect at an appropriate level of precision? | Yes | |
| 7.6. | Were other factors accounted for (measured) that could affect outcomes? | Yes | |
| 7.6. | Were other factors accounted for (measured) that could affect outcomes? | Yes | |
| 7.7. | Were the measurements conducted consistently across groups? | Yes | |
| 7.7. | Were the measurements conducted consistently across groups? | Yes | |
| 8. | Was the statistical analysis appropriate for the study design and type of outcome indicators? | Yes | |
| 8. | Was the statistical analysis appropriate for the study design and type of outcome indicators? | Yes | |
| 8.1. | Were statistical analyses adequately described and the results reported appropriately? | Yes | |
| 8.1. | Were statistical analyses adequately described and the results reported appropriately? | Yes | |
| 8.2. | Were correct statistical tests used and assumptions of test not violated? | Yes | |
| 8.2. | Were correct statistical tests used and assumptions of test not violated? | Yes | |
| 8.3. | Were statistics reported with levels of significance and/or confidence intervals? | Yes | |
| 8.3. | Were statistics reported with levels of significance and/or confidence intervals? | Yes | |
| 8.4. | Was "intent to treat" analysis of outcomes done (and as appropriate, was there an analysis of outcomes for those maximally exposed or a dose-response analysis)? | N/A | |
| 8.4. | Was "intent to treat" analysis of outcomes done (and as appropriate, was there an analysis of outcomes for those maximally exposed or a dose-response analysis)? | N/A | |
| 8.5. | Were adequate adjustments made for effects of confounding factors that might have affected the outcomes (e.g., multivariate analyses)? | Yes | |
| 8.5. | Were adequate adjustments made for effects of confounding factors that might have affected the outcomes (e.g., multivariate analyses)? | Yes | |
| 8.6. | Was clinical significance as well as statistical significance reported? | Yes | |
| 8.6. | Was clinical significance as well as statistical significance reported? | Yes | |
| 8.7. | If negative findings, was a power calculation reported to address type 2 error? | N/A | |
| 8.7. | If negative findings, was a power calculation reported to address type 2 error? | N/A | |
| 9. | Are conclusions supported by results with biases and limitations taken into consideration? | Yes | |
| 9. | Are conclusions supported by results with biases and limitations taken into consideration? | Yes | |
| 9.1. | Is there a discussion of findings? | Yes | |
| 9.1. | Is there a discussion of findings? | Yes | |
| 9.2. | Are biases and study limitations identified and discussed? | Yes | |
| 9.2. | Are biases and study limitations identified and discussed? | Yes | |
| 10. | Is bias due to study's funding or sponsorship unlikely? | Yes | |
| 10. | Is bias due to study's funding or sponsorship unlikely? | Yes | |
| 10.1. | Were sources of funding and investigators' affiliations described? | Yes | |
| 10.1. | Were sources of funding and investigators' affiliations described? | Yes | |
| 10.2. | Was the study free from apparent conflict of interest? | Yes | |
| 10.2. | Was the study free from apparent conflict of interest? | Yes | |